Identification

Name
Minocycline
Accession Number
DB01017  (APRD00547)
Type
Small Molecule
Groups
Approved, Investigational
Description

A tetracycline analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant staphylococcus infections. [PubChem]

Structure
Thumb
Synonyms
  • (4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
  • 7-Dimethylamino-6-demethyl-6-deoxytetracycline
  • Minociclina
  • Minociclinum
  • Minocyclin
  • Minocyclinum
Product Ingredients
IngredientUNIICASInChI Key
Minocycline hydrochloride0020414E5U13614-98-7GLMUAFMGXXHGLU-VQAITOIOSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ArestinPowder1 mg/1OralOrapharma Inc2011-03-21Not applicableUs
Arestin MicrospheresPowder1 mgOralOrapharma Inc2008-07-27Not applicableCanada
Dom-minocycline CapsulesCapsule100 mgOralDominion Pharmacal2000-11-24Not applicableCanada
Dom-minocycline CapsulesCapsule50 mgOralDominion Pharmacal2000-11-24Not applicableCanada
Enca 100mgCapsule100 mgOralPrempharm Inc2003-10-032009-08-05Canada
Enca 50mgCapsule50 mgOralPrempharm Inc2003-10-032009-08-05Canada
MinocinCapsule100 mgOralGlaxosmithkline Inc1996-10-252012-12-10Canada
MinocinKitOnset Dermatologics, LLC2013-06-172016-01-31Us
MinocinCapsule, coated pellets50 mg/1OralOnset Dermatologics, LLC1990-05-31Not applicableUs
MinocinCapsule, coated pellets75 mg/1OralOnset Dermatologics, LLC1990-05-312017-05-20Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-minocycline Cap 100mgCapsule100 mgOralApotex Corporation1994-12-31Not applicableCanada
Apo-minocycline Cap 50mgCapsule50 mgOralApotex Corporation1994-12-31Not applicableCanada
DynacinTablet75 mg/1OralPar Pharmaceutical2011-06-20Not applicableUs
DynacinTablet50 mg/1OralPar Pharmaceutical2011-06-20Not applicableUs
DynacinTablet100 mg/1OralPar Pharmaceutical2011-06-20Not applicableUs
MinocyclineTablet50 mg/1OralAv Kare, Inc.2015-05-08Not applicableUs
MinocyclineTablet, film coated75 mg/1OralSun Pharmaceuticals Industries, Inc.2016-01-29Not applicableUs
MinocyclineTablet50 mg/1OralPar Pharmaceutical2003-04-16Not applicableUs
MinocyclineTablet100 mg/1OralPar Pharmaceutical2003-04-16Not applicableUs49884 0513 03 nlmimage10 881b441a
MinocyclineTablet100 mg/1OralAv Kare, Inc.2015-05-08Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Minocycline HydrochlorideCapsule50 mg/1OralAlvogen, Inc.2017-10-31Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralAlvogen, Inc.2017-10-31Not applicableUs
Minocycline HydrochlorideCapsule50 mg/1OralNu Care Pharmaceuticals,inc.1991-12-30Not applicableUs
Minocycline HydrochlorideCapsule75 mg/1OralAlvogen, Inc.2017-10-31Not applicableUs
Minocycline HydrochlorideCapsule100 mg/1OralPreferreed Pharmaceuticals Inc.2017-11-06Not applicableUs
International/Other Brands
Aknemin / Apo-Minocycline / Klinomycin / Minoderm / Minomycin / Minopen / Minox / Minoz / Vectrin
Categories
UNII
FYY3R43WGO
CAS number
10118-90-8
Weight
Average: 457.4764
Monoisotopic: 457.184900233
Chemical Formula
C23H27N3O7
InChI Key
DYKFCLLONBREIL-KVUCHLLUSA-N
InChI
InChI=1S/C23H27N3O7/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32)/t9-,11-,17-,23-/m0/s1
IUPAC Name
(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
SMILES
[H][[email protected]@]12CC3=C(C(O)=CC=C3N(C)C)C(=O)C1=C(O)[[email protected]]1(O)C(=O)C(C(N)=O)=C(O)[[email protected]@H](N(C)C)[[email protected]]1([H])C2

Pharmacology

Indication

For the treatment of infections caused by susceptible strains of microorganisms, such as Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsial pox and tick fevers caused by Rickettsiae, upper respiratory tract infections caused by Streptococcus pneumoniae and for the treatment of asymptomatic carriers of Neisseria meningitidis.

Structured Indications
Pharmacodynamics

Minocycline, the most lipid soluble and most active tetracycline antibiotic, is, like doxycycline, a long-acting tetracycline. Minocycline's effects are related to the inhibition of protein synthesis. Although minocycline's broader spectrum of activity, compared to other members of the group, includes activity against Neisseria meningitidis, its use as a prophylaxis is no longer recomended because of side effects (dizziness and vertigo). Current research is examining the possible neuroprotective effects of minocycline against progression of Huntington's Disease, an inherited neurodegenerative disorder. The neuroprotective action of minocycline may include its inhibitory effect on 5-lipoxygenase, an inflammatory enzyme associated with brain aging.

Mechanism of action

Minocycline passes directly through the lipid bilayer or passively diffuses through porin channels in the bacterial membrane. Tetracyclines like minocycline bind to the 30S ribosomal subunit, preventing the binding of tRNA to the mRNA-ribosome complex and interfering with protein synthesis.

TargetActionsOrganism
A30S ribosomal protein S9
inhibitor
Escherichia coli (strain K12)
A30S ribosomal protein S4
inhibitor
Escherichia coli (strain K12)
U16S rRNA
inhibitor
Enteric bacteria and other eubacteria
UInterleukin-1 beta
modulator
Human
UArachidonate 5-lipoxygenase
inhibitor
Human
UMatrix metalloproteinase-9
inhibitor
Human
UVascular endothelial growth factor A
inhibitor
Human
UCaspase-1
negative modulator
Human
UCaspase-3
negative modulator
Human
UCytochrome c
negative modulator
Human
Absorption

Rapidly absorbed from the gastrointestinal tract and absorption is not significantly impaired by ingestion of food or milk. Oral bioavailability is 100%.

Volume of distribution
Not Available
Protein binding

55% to 76%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

11-22 hours

Clearance
Not Available
Toxicity

Minocycline has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs and monkeys). In the rat, chronic treatment with minocycline has resulted in goiter accompanied by elevated radioactive iodine uptake and evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. LD50=2380 mg/kg (rat, oral), LD50=3600 mg/kg (mouse, oral)

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
PathwayCategory
Minocycline Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
AcenocoumarolMinocycline may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
AcitretinThe risk or severity of adverse effects can be increased when Minocycline is combined with Acitretin.Approved
AdapaleneThe risk or severity of adverse effects can be increased when Minocycline is combined with Adapalene.Approved
AdipiplonMinocycline may increase the central nervous system depressant (CNS depressant) activities of Adipiplon.Investigational
AgomelatineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
AlcuroniumMinocycline may increase the neuromuscular blocking activities of Alcuronium.Experimental
AlfaxaloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AlitretinoinThe risk or severity of adverse effects can be increased when Minocycline is combined with Alitretinoin.Approved, Investigational
AllopregnanoloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Allopregnanolone.Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
AlphacetylmethadolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine.Illicit
AlprazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
AluminiumAluminium can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmdinocillinThe therapeutic efficacy of Amdinocillin can be decreased when used in combination with Minocycline.Investigational, Withdrawn
AmisulprideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
AmitriptylineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmoxapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmoxicillinThe therapeutic efficacy of Amoxicillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
AmperozideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
AmpicillinThe therapeutic efficacy of Ampicillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
AripiprazoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
ArticaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AspoxicillinThe therapeutic efficacy of Aspoxicillin can be decreased when used in combination with Minocycline.Experimental
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Minocycline.Approved, Investigational
AtracuriumMinocycline may increase the neuromuscular blocking activities of Atracurium.Experimental, Investigational
Atracurium besylateMinocycline may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Investigational, Vet Approved
AzelastineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzidocillinThe therapeutic efficacy of Azidocillin can be decreased when used in combination with Minocycline.Approved
AzlocillinThe therapeutic efficacy of Azlocillin can be decreased when used in combination with Minocycline.Approved
BacampicillinThe therapeutic efficacy of Bacampicillin can be decreased when used in combination with Minocycline.Approved, Investigational
BaclofenMinocycline may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
BarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Minocycline.Investigational
BenperidolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Investigational
Benzathine benzylpenicillinThe therapeutic efficacy of Benzathine benzylpenicillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
BenzocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
Benzyl alcoholMinocycline may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
BenzylpenicillinThe therapeutic efficacy of Benzylpenicillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe therapeutic efficacy of Benzylpenicilloyl Polylysine can be decreased when used in combination with Minocycline.Approved
BexaroteneThe risk or severity of adverse effects can be increased when Minocycline is combined with Bexarotene.Approved, Investigational
Bismuth SubcitrateThe serum concentration of Minocycline can be decreased when it is combined with Bismuth Subcitrate.Approved
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Bismuth SubsalicylateThe serum concentration of Minocycline can be decreased when it is combined with Bismuth Subsalicylate.Approved, Vet Approved
BrexpiprazoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
BrimonidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
BromazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
BromisovalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Bromisoval.Experimental
BromperidolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Bromperidol.Investigational
BrompheniramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Investigational, Withdrawn
BupivacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BuprenorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
ButethalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButorphanolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
Calcium AcetateThe serum concentration of Minocycline can be decreased when it is combined with Calcium Acetate.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium ChlorideThe serum concentration of Minocycline can be decreased when it is combined with Calcium Chloride.Approved
Calcium CitrateThe serum concentration of Minocycline can be decreased when it is combined with Calcium Citrate.Approved
Calcium glubionateThe serum concentration of Minocycline can be decreased when it is combined with Calcium glubionate.Approved
Calcium GluceptateThe serum concentration of Minocycline can be decreased when it is combined with Calcium Gluceptate.Approved
Calcium gluconateThe serum concentration of Minocycline can be decreased when it is combined with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe serum concentration of Minocycline can be decreased when it is combined with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe serum concentration of Minocycline can be decreased when it is combined with Calcium lactate gluconate.Experimental
Calcium laevulateThe serum concentration of Minocycline can be decreased when it is combined with Calcium laevulate.Experimental
Calcium pangamateThe serum concentration of Minocycline can be decreased when it is combined with Calcium pangamate.Experimental
Calcium PhosphateThe serum concentration of Minocycline can be decreased when it is combined with Calcium Phosphate.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanertinibMinocycline may increase the central nervous system depressant (CNS depressant) activities of Canertinib.Investigational
CarbamazepineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbenicillinThe therapeutic efficacy of Carbenicillin can be decreased when used in combination with Minocycline.Approved, Investigational
Carbenicillin indanylThe therapeutic efficacy of Carbenicillin indanyl can be decreased when used in combination with Minocycline.Approved, Investigational
CarbinoxamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarfecillinThe therapeutic efficacy of Carfecillin can be decreased when used in combination with Minocycline.Experimental
CarfentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CaseinThe serum concentration of Minocycline can be decreased when it is combined with Casein.Approved
CetirizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydrateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit
ChlormezanoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChlorphenamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorpromazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinchocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
CisatracuriumMinocycline may increase the neuromuscular blocking activities of Cisatracurium.Approved, Experimental
Cisatracurium besylateMinocycline may increase the neuromuscular blocking activities of Cisatracurium besylate.Approved
ClemastineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved
ClidiniumMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClobazamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
clomethiazoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
ClonazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
ClopenthixolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol.Experimental
ClorazepateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
ClorindioneMinocycline may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clothiapine.Experimental
CloxacillinThe therapeutic efficacy of Cloxacillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
ClozapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CyclacillinThe therapeutic efficacy of Cyclacillin can be decreased when used in combination with Minocycline.Approved
CyclizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyproheptadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DantroleneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
DapiprazoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DecamethoniumMinocycline may increase the neuromuscular blocking activities of Decamethonium.Approved
DeramciclaneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Deramciclane.Investigational
DesfluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
DesloratadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DetomidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DexbrompheniramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexmedetomidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DextromoramideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved, Investigational
DiazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Vet Approved
DicloxacillinThe therapeutic efficacy of Dicloxacillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
DicoumarolMinocycline may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diethyl ether.Experimental
DifenoxinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DihydrocodeineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DiphenadioneMinocycline may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
DiphenoxylateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
DixyrazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dixyrazine.Experimental
Domoic AcidMinocycline may increase the neuromuscular blocking activities of Domoic Acid.Experimental
DoramectinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
Doxacurium chlorideMinocycline may increase the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxepinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
DoxylamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Vet Approved
DPDPEMinocycline may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Experimental
DroperidolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Droperidol.Approved, Vet Approved
DrotebanolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DyclonineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgonineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
EcopipamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzMinocycline may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EltanoloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Eltanolone.Investigational
EnfluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Investigational, Vet Approved
EntacaponeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
EpicillinThe therapeutic efficacy of Epicillin can be decreased when used in combination with Minocycline.Experimental
EstazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EszopicloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
EthanolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl biscoumacetateMinocycline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl chlorideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethyl chloride.Experimental, Investigational
Ethyl loflazepateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
EtidocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
EtifoxineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Investigational, Withdrawn
EtizolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtomidateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EzogabineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved
FelbamateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FencamfamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FentanylMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseMinocycline can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateMinocycline can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric pyrophosphateMinocycline can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
FlibanserinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
FluanisoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluanisone.Experimental
FlucloxacillinThe therapeutic efficacy of Flucloxacillin can be decreased when used in combination with Minocycline.Approved, Investigational
FludiazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FluindioneMinocycline may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FlupentixolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Withdrawn
FluphenazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit
FluspirileneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Investigational
Fluticasone propionateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved
FluvoxamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FosphenytoinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.Approved
FospropofolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit, Investigational
GabapentinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
Gabapentin EnacarbilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved
GallamineMinocycline may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideMinocycline may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidMinocycline may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepironeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GlutethimideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GuanfacineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
HalazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HaloperidolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HalothaneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HeroinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit, Investigational
HexobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HydrocodoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
HydroxyzineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.Approved
IloperidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
ImipramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IndiplonMinocycline may increase the central nervous system depressant (CNS depressant) activities of Indiplon.Investigational
IronMinocycline can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranMinocycline can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateThe serum concentration of Minocycline can be decreased when it is combined with Iron saccharate.Approved
IsofluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
IsotretinoinThe risk or severity of adverse effects can be increased when Minocycline is combined with Isotretinoin.Approved
KetamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Investigational
LamotrigineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
Lanthanum carbonateThe serum concentration of Minocycline can be decreased when it is combined with Lanthanum carbonate.Approved
LevetiracetamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobupivacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved, Investigational
LevocabastineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved
LevocetirizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
Levomethadyl AcetateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Investigational
LevorphanolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LidocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
LithiumMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
LofentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LoprazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Loprazolam.Experimental
LoratadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
LorazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LormetazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved
LoxapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
LurasidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium HydroxideMagnesium Hydroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateMagnesium salicylate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Magnesium SulfateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
MebicarMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mebicar.Experimental
MecamylamineMinocycline may increase the neuromuscular blocking activities of Mecamylamine.Approved
MeclizineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Medazepam.Experimental
MedetomidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
MelatoninMinocycline may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved, Investigational
MepivacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MeptazinolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.Experimental
MesoridazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Investigational
MetampicillinThe therapeutic efficacy of Metampicillin can be decreased when used in combination with Minocycline.Experimental
MetaxaloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MethadoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethapyrileneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethocarbamolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethotrimeprazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethylecgonineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Experimental
MethylphenobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MeticillinThe therapeutic efficacy of Meticillin can be decreased when used in combination with Minocycline.Approved, Investigational
MetocurineMinocycline may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideMinocycline may increase the neuromuscular blocking activities of Metocurine Iodide.Withdrawn
MezlocillinThe therapeutic efficacy of Mezlocillin can be decreased when used in combination with Minocycline.Approved, Investigational
MidazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MipomersenMinocycline may increase the hepatotoxic activities of Mipomersen.Approved
MirtazapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumMinocycline may increase the neuromuscular blocking activities of Mivacurium.Approved
MolindoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MorphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
NabiloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Investigational
NafcillinThe therapeutic efficacy of Nafcillin can be decreased when used in combination with Minocycline.Approved
NalbuphineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
NeosaxitoxinMinocycline may increase the neuromuscular blocking activities of Neosaxitoxin.Investigational
NitrazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
Nitrous oxideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NorfluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Norflurane.Investigational
NormethadoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
OlanzapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OlopatadineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OndansetronMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpiumMinocycline may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrphenadrineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantMinocycline may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OxacillinThe therapeutic efficacy of Oxacillin can be decreased when used in combination with Minocycline.Approved
OxazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxethazaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxethazaine.Approved, Investigational
OxprenololMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
OxybuprocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved
OxycodoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PancuroniumMinocycline may increase the neuromuscular blocking activities of Pancuronium.Approved
ParaldehydeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PenamecillinThe therapeutic efficacy of Penamecillin can be decreased when used in combination with Minocycline.Experimental
PenfluridolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Penfluridol.Experimental
PenimepicyclineThe therapeutic efficacy of Penimepicycline can be decreased when used in combination with Minocycline.Experimental
PentazocineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
PerampanelMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perampanel.Approved
PerazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perazine.Investigational
PerospironeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenazocineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenazocine.Experimental
PhenibutMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenibut.Experimental
PhenindioneMinocycline may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved
PhenoperidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenoperidine.Experimental
PhenoxyethanolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhenoxymethylpenicillinThe therapeutic efficacy of Phenoxymethylpenicillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
PhenprocoumonMinocycline may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Minocycline.Approved
PimozideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PipamperoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Investigational
PipecuroniumMinocycline may increase the neuromuscular blocking activities of Pipecuronium.Approved
PiperacillinThe therapeutic efficacy of Piperacillin can be decreased when used in combination with Minocycline.Approved
PipotiazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved, Investigational
PiritramideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Investigational
PivampicillinThe therapeutic efficacy of Pivampicillin can be decreased when used in combination with Minocycline.Approved
PivmecillinamThe therapeutic efficacy of Pivmecillinam can be decreased when used in combination with Minocycline.Approved
PizotifenMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
PomalidomideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PramocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PrazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PregabalinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PrilocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Primidone.Approved, Vet Approved
ProcaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
Procaine benzylpenicillinThe therapeutic efficacy of Procaine benzylpenicillin can be decreased when used in combination with Minocycline.Approved, Vet Approved
ProchlorperazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
PromazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
PropanididMinocycline may increase the central nervous system depressant (CNS depressant) activities of Propanidid.Experimental
ProparacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropicillinThe therapeutic efficacy of Propicillin can be decreased when used in combination with Minocycline.Experimental
PropofolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
ProtriptylineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
ProxibarbalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Proxibarbal.Experimental
PSD502Minocycline may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
PyrantelMinocycline may increase the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
QuinaprilThe serum concentration of Minocycline can be decreased when it is combined with Quinapril.Approved, Investigational
QuinisocaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Quinisocaine.Experimental
RacloprideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RamelteonMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RapacuroniumMinocycline may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemoxiprideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
ReserpineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved, Investigational
RisperidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
RitanserinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RocuroniumMinocycline may increase the neuromuscular blocking activities of Rocuronium.Approved
RomifidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopivacaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
ScopolamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
SecobarbitalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SepranoloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sepranolone.Investigational
SertindoleMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Investigational, Withdrawn
SevofluraneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium oxybateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.Approved
StiripentolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
Strontium ranelateThe serum concentration of Minocycline can be decreased when it is combined with Strontium ranelate.Approved
SuccinylcholineMinocycline may increase the neuromuscular blocking activities of Succinylcholine.Approved
SucralfateSucralfate can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SufentanilMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulbactamThe therapeutic efficacy of Sulbactam can be decreased when used in combination with Minocycline.Approved
SulbenicillinThe therapeutic efficacy of Sulbenicillin can be decreased when used in combination with Minocycline.Experimental
SulpirideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Investigational
SultamicillinThe therapeutic efficacy of Sultamicillin can be decreased when used in combination with Minocycline.Investigational
SultoprideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sultopride.Experimental
SuvorexantMinocycline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TalampicillinThe therapeutic efficacy of Talampicillin can be decreased when used in combination with Minocycline.Experimental
TandospironeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tapentadol.Approved
TasimelteonMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved
TazobactamThe therapeutic efficacy of Tazobactam can be decreased when used in combination with Minocycline.Approved
TemazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
TetrabenazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
TetracaineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetrahydropalmatineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Investigational
TetrodotoxinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
ThalidomideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioridazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Withdrawn
ThiothixeneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TiagabineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
TiaprideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Investigational
TicarcillinThe therapeutic efficacy of Ticarcillin can be decreased when used in combination with Minocycline.Approved, Investigational, Vet Approved
TiletamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TilidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tilidine.Experimental
TioclomarolMinocycline may increase the anticoagulant activities of Tioclomarol.Experimental
TizanidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
TolcaponeMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
TopiramateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
TramadolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
TrazodoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Minocycline is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriazolamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
Tricaine methanesulfonateMinocycline may increase the central nervous system depressant (CNS depressant) activities of Tricaine methanesulfonate.Vet Approved
TrichloroethyleneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trichloroethylene.Approved
TrifluoperazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TrifluperidolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trifluperidol.Experimental
TriflupromazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrimipramineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
TromethamineTromethamine can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TubocurarineMinocycline may increase the neuromuscular blocking activities of Tubocurarine.Approved
Valproic AcidMinocycline may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
VecuroniumMinocycline may increase the neuromuscular blocking activities of Vecuronium.Approved
VeraliprideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Veralipride.Experimental
VigabatrinMinocycline may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
Vinyl etherMinocycline may increase the central nervous system depressant (CNS depressant) activities of Vinyl ether.Experimental
VortioxetineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
WarfarinMinocycline may increase the anticoagulant activities of Warfarin.Approved
XenonMinocycline may increase the central nervous system depressant (CNS depressant) activities of Xenon.Experimental
XylazineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
ZaleplonMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZiconotideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZiprasidoneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZolazepamMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
ZolpidemMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopicloneMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved, Investigational
ZuclopenthixolMinocycline may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Calcium and iron needs increased with long term use.
  • Do not take Aluminum or magnesium antacids or supplements while on this medication.
  • Take with food.

References

Synthesis Reference

Zita Mendes, Jose Rafael Antunes, Susana Marto, William Heggie, "Crystalline Minocycline Base and Processes for its Preparation." U.S. Patent US20100286417, issued November 11, 2010.

US20100286417
General References
  1. Gough A, Chapman S, Wagstaff K, Emery P, Elias E: Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996 Jan 20;312(7024):169-72. [PubMed:8563540]
  2. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. [PubMed:10888929]
  3. Tikka TM, Koistinaho JE: Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol. 2001 Jun 15;166(12):7527-33. [PubMed:11390507]
  4. Nirmalananthan N, Greensmith L: Amyotrophic lateral sclerosis: recent advances and future therapies. Curr Opin Neurol. 2005 Dec;18(6):712-9. [PubMed:16280684]
  5. Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z: Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004 Oct 5;15(14):2181-4. [PubMed:15371729]
  6. Link [Link]
External Links
Human Metabolome Database
HMDB15152
KEGG Drug
D05045
KEGG Compound
C07225
PubChem Compound
54675783
PubChem Substance
46504772
ChemSpider
16735907
BindingDB
50046515
ChEBI
50694
ChEMBL
CHEMBL1434
Therapeutic Targets Database
DAP000405
PharmGKB
PA450519
HET
MIY
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Minocycline
ATC Codes
A01AB23 — MinocyclineJ01AA20 — Combinations of tetracyclinesJ01AA08 — Minocycline
AHFS Codes
  • 52:04.04 — Antibacterials
  • 08:12.24 — Tetracyclines
PDB Entries
2drd / 2wq5 / 2xpv / 3aod / 3v3n / 4a99 / 4ac0 / 4dx5 / 4u8v / 4u8y
show 2 more
FDA label
Download (3.02 MB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic ScienceMajor Depressive Disorder (MDD)1
0RecruitingTreatmentOsteomyelitis1
1CompletedOtherSkin Infections (Acne)1
1CompletedTreatmentAneurysms / Arteriovenous Malformations1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPrimary Sclerosing Cholangitis (PSC)1
1CompletedTreatmentSkin Diseases1
1Not Yet RecruitingTreatmentHealthy Volunteers / Renal Insufficiency, Acute / Renal Insufficiency,Chronic1
1Not Yet RecruitingTreatmentNormal Healthy Volunteers1
1Not Yet RecruitingTreatmentPeriapical Periodontitis1
1RecruitingTreatmentAlcohol Dependence1
1RecruitingTreatmentAutism Spectrum Conditions/Disorders1
1RecruitingTreatmentGlioblastomas1
1RecruitingTreatmentHigh Blood Pressure (Hypertension)1
1RecruitingTreatmentIrradiation; Adverse Effect1
1RecruitingTreatmentNormal Healthy Volunteers1
1RecruitingTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
1TerminatedTreatmentStrokes1
1Unknown StatusTreatmentUnipolar Depression1
1, 2CompletedTreatmentDiabetic Macular Edema (DME)1
1, 2CompletedTreatmentFirst Episode Psychosis1
1, 2CompletedTreatmentHuntington's Disease (HD)1
1, 2CompletedTreatmentIntracerebral Hemorrhage1
1, 2CompletedTreatmentRetinitis Pigmentosa (RP)1
1, 2CompletedTreatmentSpinal Cord Injuries (SCI)1
1, 2CompletedTreatmentStroke, Acute1
1, 2Not Yet RecruitingTreatmentAlcohol Drinking / Alcohol Use Disorder (AUD) / Craving / Inflammatory Reaction / Neurocognitive Dysfunction1
1, 2RecruitingTreatmentBrain Injury1
1, 2RecruitingTreatmentIntracerebral Hemorrhage1
1, 2RecruitingTreatmentRecurrent Gliomas1
1, 2RecruitingTreatmentRetinal Vein Occlusions(RVO)2
1, 2RecruitingTreatmentSubarachnoid Aneurysm Hemorrhage1
1, 2TerminatedTreatmentHIV-associated Cognitive Impairment / Human Immunodeficiency Virus (HIV) Infections1
1, 2TerminatedTreatmentHead and Neck Carcinoma1
1, 2Unknown StatusTreatmentTraumatic Brain Injury (TBI)1
1, 2WithdrawnSupportive CareLung Cancer Non-Small Cell Cancer (NSCLC)1
2Active Not RecruitingTreatmentAcne Vulgaris1
2Active Not RecruitingTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentHead and Neck Carcinoma1
2Active Not RecruitingTreatmentLung Cancers1
2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
2Active Not RecruitingTreatmentObsessive Compulsive Disorder (OCD)1
2Active Not RecruitingTreatmentOropharynx Cancers1
2Active Not RecruitingTreatmentPlasma Cell Myeloma2
2CompletedTreatmentAlzheimer's Disease (AD) / Mild Cognitive Impairment (MCI)1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAngelman's syndrome1
2CompletedTreatmentCystic Fibrosis (CF) / Methicillin-Resistant Staphylococcus Aureus (MRSA)1
2CompletedTreatmentEsophageal Cancers1
2CompletedTreatmentParkinson's Disease (PD)1
2CompletedTreatmentRash1
2CompletedTreatmentSchizophrenia and Disorders With Psychotic Features1
2Enrolling by InvitationTreatmentFragile X Syndrome (FXS)1
2RecruitingBasic ScienceBack Pain / Back Pain Lower Back Chronic / Back Pain With Radiation / Back Pain Without Radiation / Low Back Pain (LBP) / Pain, Chronic1
2RecruitingTreatmentAge- Related Macular Degeneration1
2RecruitingTreatmentAt Risk Mental State (ARMS) / Psychosis1
2RecruitingTreatmentFragile X Syndrome (FXS)1
2RecruitingTreatmentMajor Depressive Disorder (MDD)1
2TerminatedTreatmentDepressive Disorders1
2TerminatedTreatmentDisseminated Sclerosis / Optic Neuritis1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2TerminatedTreatmentObsessive Compulsive Disorder (OCD)1
2TerminatedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
2Unknown StatusPreventionPain, Chronic / Post-Operative Pain1
2Unknown StatusPreventionRetinal Detachment1
2Unknown StatusTreatmentAsthma Bronchial2
2Unknown StatusTreatmentPost-operative Intercostal Neuralgia1
2WithdrawnPreventionCarotid Stenosis1
2, 3Active Not RecruitingTreatmentStroke, Ischemic1
2, 3CompletedTreatmentHuntington's Disease (HD)1
2, 3Unknown StatusPreventionSpinal Tumors, Trauma Patients, Minocycline1
3CompletedPreventionClinically Isolated Syndrome (CIS) / Early Single Relapse of Multiple Sclerosis1
3CompletedPreventionNegative and Cognitive Symptoms in Schizophrenia1
3CompletedTreatmentAdult Periodontitis1
3CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
3CompletedTreatmentBipolar Disorder (BD) / Bipolar II Depression / Depression, Bipolar1
3CompletedTreatmentBipolar Disorder Depression1
3CompletedTreatmentPeri-Implantitis2
3CompletedTreatmentPeriodontitis1
3CompletedTreatmentRheumatoid Arthritis1
3RecruitingPreventionCarcinoma of the Rectum / Malignant Neoplasm of Colon / Prostate Cancer / Renal Carcinoma1
3RecruitingPreventionPeriodontal Diseases / Strokes / Transient Ischaemic Attack (TIA)1
3RecruitingTreatmentAmphetamine Dependence / Heroin Dependence1
3RecruitingTreatmentBipolar Disorder (BD) / Depression / Depression, Bipolar / Moods Disorders1
3RecruitingTreatmentSchizophrenic Disorders1
3RecruitingTreatmentSpinal Cord Injuries (SCI)1
3TerminatedTreatmentAcne Vulgaris1
3Unknown StatusTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3Unknown StatusTreatmentOral Lichen Planus1
3Unknown StatusTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentAcne1
4CompletedTreatmentAntidepressive Agents / Depressive Disorder, Treatment Resistant / Depressive Disorders / Moods Disorders1
4CompletedTreatmentAutism, Early Infantile / Minocycline / Regressive Autism1
4CompletedTreatmentChronic Periodontitis1
4CompletedTreatmentDepression, Bipolar1
4CompletedTreatmentHuman Volunteers1
4CompletedTreatmentModerate to Advanced Chronic Periodontitis1
4CompletedTreatmentNeuropathic Pain Caused by Lumbar Radicular Pain1
4CompletedTreatmentPeriodontitis1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentSchizophrenic Disorders2
4RecruitingOtherSchizophrenic Disorders / Tobacco Use1
4RecruitingTreatmentBipolar Disorder (BD) / Depression, Bipolar1
4RecruitingTreatmentPTSD1
4TerminatedTreatmentAcne Vulgaris1
4TerminatedTreatmentStroke, Acute1
4Unknown StatusTreatmentSchizophrenic Disorders1
4Unknown StatusTreatmentBacterial blepharitis1
4WithdrawnTreatmentLiver Diseases1
Not AvailableActive Not RecruitingTreatmentChronic Kidney Disease (CKD) / Periodontal Diseases1
Not AvailableCompletedNot AvailableHealthy Volunteers4
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedBasic ScienceOpioid Dependence / Pain1
Not AvailableCompletedPreventionAcute Kidney Insufficiency / Kidney Failures, Acute1
Not AvailableCompletedPreventionMethicillin Resistant Staphylococcus Aureus Skin Infections1
Not AvailableCompletedSupportive CareCancer, Breast / Carcinoma, Breast / Pain, Acute / Peripheral Neuropathy1
Not AvailableCompletedSupportive CareLung Cancers1
Not AvailableCompletedTreatmentFragile X Syndrome (FXS)2
Not AvailableCompletedTreatmentMeibomian Gland Dysfunction (MGD)1
Not AvailableCompletedTreatmentSchizophrenic Disorders1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD) / BMI >30 kg/m2 / Depression1
Not AvailableRecruitingNot AvailableGram-Negative Bacterial Infections1
Not AvailableRecruitingHealth Services ResearchMemory Disturbances1
Not AvailableRecruitingPreventionNonvalvular Atrial Fibrillation1
Not AvailableRecruitingSupportive CareAnxiety Disorders / Depression / Recurrent Breast Cancer / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
Not AvailableTerminatedTreatmentAcute Ischemic Stroke (AIS)1
Not AvailableUnknown StatusTreatmentAngelman's syndrome1
Not AvailableUnknown StatusTreatmentDepression1
Not AvailableUnknown StatusTreatmentDiabetic Nephropathies1
Not AvailableUnknown StatusTreatmentSchizophrenic Disorders1
Not AvailableWithdrawnSupportive CareCancers1

Pharmacoeconomics

Manufacturers
  • Medicis pharmaceutical corp
  • Triax pharmaceuticals llc
  • Aurobindo pharma ltd
  • Impax laboratories inc
  • Ranbaxy laboratories ltd
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Lederle laboratories div american cyanamid co
  • Orapharma inc
  • Barr laboratories inc
  • Matrix laboratories ltd
  • Sandoz inc
  • Dr reddys laboratories ltd
  • Medicis Pharmaceutical Corporation
Packagers
Dosage forms
FormRouteStrength
CapsuleOral100 mg
CapsuleOral50 mg
PowderOral1 mg/1
PowderOral1 mg
TabletOral75 mg/1
Capsule, coated pelletsOral75 mg/1
InjectionIntravenous100 mg/1
Kit
Capsule, coated pelletsOral100 mg/1
Capsule, coated pelletsOral50 mg/1
TabletOral100 mg/1
TabletOral50 mg/1
CapsuleOral100 mg/1
CapsuleOral50 mg/1
CapsuleOral75 mg/1
Tablet, extended releaseOral135 mg/1
Tablet, extended releaseOral45 mg/1
Tablet, extended releaseOral90 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral75 mg/1
Tablet, film coated, extended releaseOral135 mg/1
Tablet, film coated, extended releaseOral45 mg/1
Tablet, film coated, extended releaseOral90 mg/1
Tablet, extended releaseOral105 mg/1
Tablet, film coated, extended releaseOral105 mg/1
Tablet, film coated, extended releaseOral115 mg/1
Tablet, film coated, extended releaseOral55 mg/1
Tablet, film coated, extended releaseOral65 mg/1
Tablet, film coated, extended releaseOral80 mg/1
Capsule, extended releaseOral135 mg/1
Capsule, extended releaseOral45 mg/1
Capsule, extended releaseOral90 mg/1
Prices
Unit descriptionCostUnit
Minocin PAC 100 mg Kit Box695.5USD box
Minocin kit 100 mg combo668.17USD kit
Minocin kit 50 mg combo334.78USD kit
Minocin 100 mg vial59.64USD vial
Arestin 1 mg microsphere30.0USD each
Solodyn 135 mg 24 Hour tablet24.89USD tablet
Solodyn 45 mg 24 Hour tablet24.89USD tablet
Solodyn 65 mg 24 Hour tablet24.89USD tablet
Solodyn 90 mg 24 Hour tablet24.89USD tablet
Solodyn er 115 mg tablet23.93USD tablet
Solodyn er 135 mg tablet23.93USD tablet
Solodyn er 45 mg tablet23.93USD tablet
Solodyn er 65 mg tablet23.93USD tablet
Solodyn er 90 mg tablet23.93USD tablet
Minocycline hcl powder21.0USD g
Minocycline HCl 135 mg 24 Hour tablet19.21USD tablet
Minocycline HCl 45 mg 24 Hour tablet19.21USD tablet
Dynacin 100 mg tablet13.37USD tablet
Dynacin 75 mg tablet13.12USD tablet
Minocin 100 mg capsule12.05USD capsule
Minocin 100 mg pelletized cap11.11USD pellet
Dynacin 50 mg tablet8.76USD tablet
Dynacin 75 mg capsule7.15USD capsule
Minocycline hcl 100 mg tablet6.15USD tablet
Minocin 50 mg pelletized cap5.56USD pellet
Minocin 50 mg capsule5.24USD capsule
Minocycline hcl 75 mg tablet5.14USD tablet
Dynacin 50 mg capsule3.85USD capsule
Minocycline HCl 100 mg capsule3.53USD capsule
Minocycline hcl 50 mg tablet3.5USD tablet
Minocycline HCl 75 mg capsule2.06USD capsule
Minocycline 75 mg capsule1.98USD capsule
Minocycline HCl 50 mg capsule1.77USD capsule
Minocin 100 mg Capsule1.34USD capsule
Apo-Minocycline 100 mg Capsule1.08USD capsule
Minocycline 100 mg Capsule1.08USD capsule
Mylan-Minocycline 100 mg Capsule1.08USD capsule
Novo-Minocycline 100 mg Capsule1.08USD capsule
Pms-Minocycline 100 mg Capsule1.08USD capsule
Ratio-Minocycline 100 mg Capsule1.08USD capsule
Sandoz Minocycline 100 mg Capsule1.08USD capsule
Minocin 50 mg Capsule0.69USD capsule
Apo-Minocycline 50 mg Capsule0.56USD capsule
Minocycline 50 mg Capsule0.56USD capsule
Mylan-Minocycline 50 mg Capsule0.56USD capsule
Novo-Minocycline 50 mg Capsule0.56USD capsule
Pms-Minocycline 50 mg Capsule0.56USD capsule
Ratio-Minocycline 50 mg Capsule0.56USD capsule
Sandoz Minocycline 50 mg Capsule0.56USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1330533No1994-07-052011-07-05Canada
US5908838No1998-02-192018-02-19Us
US7790705No2005-06-242025-06-24Us
US7919483No2007-03-072027-03-07Us
US8252776No2005-06-242025-06-24Us
US8268804No2005-06-242025-06-24Us
US8722650No2005-06-242025-06-24Us
US9192615No2011-11-172031-11-17Us
US7541347No2007-04-022027-04-02Us
US7544373No2007-04-022027-04-02Us
US9278105No2011-05-122031-05-12Us
US9084802No2011-05-122031-05-12Us
US7699609No2002-03-292022-03-29Us
US6682348No2002-03-292022-03-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubility5.2E+004 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.05SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility3.07 mg/mLALOGPS
logP-0.03ALOGPS
logP-3.3ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)-2.3ChemAxon
pKa (Strongest Basic)8.25ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area164.63 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity122.54 m3·mol-1ChemAxon
Polarizability45.9 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7469
Blood Brain Barrier-0.9783
Caco-2 permeable+0.5711
P-glycoprotein substrateSubstrate0.7366
P-glycoprotein inhibitor INon-inhibitor0.7968
P-glycoprotein inhibitor IINon-inhibitor0.7036
Renal organic cation transporterNon-inhibitor0.9536
CYP450 2C9 substrateNon-substrate0.8145
CYP450 2D6 substrateNon-substrate0.9036
CYP450 3A4 substrateSubstrate0.6805
CYP450 1A2 substrateNon-inhibitor0.9088
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9081
CYP450 3A4 inhibitorNon-inhibitor0.9058
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7561
Ames testNon AMES toxic0.8909
CarcinogenicityNon-carcinogens0.9091
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4354 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9954
hERG inhibition (predictor II)Non-inhibitor0.6783
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0001900000-6e678a7f126753a02d03
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00dr-0139100000-ff75a26ae387147257db
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0293000000-c2ff616578522f961ba6
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0390000000-d52131f98ad1d88e178c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0fki-1690000000-e5a98a7122d0379c17ce
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00dr-1980000000-8e1add1bcba675eab919
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00di-2940000000-5fb719a03faa19bc3ece
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-6920000000-fb4c9cde9587edd4015e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-9300000000-6299955440e9be195128
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a4i-0000900000-6f7513e3aaa9e86725ec
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0a4i-0011900000-ed3a433871dc9cea2d9f
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00dr-0559300000-4e1a4ba6692c21980cae
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-00dr-0696000000-f57972687a1b0ffe9411
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-000i-1491000000-1847e0c78206ea2f84c3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4l-0000900000-ae91ec031bca8b95216e
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-0001900000-0bc6e4a0b16f4acd3d1d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0uei-1149100000-2ea03125f37fabe56999
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001r-1192000000-476045d8accb26d18bb4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-015i-1390000000-f6a75360809f9018052a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-015i-1890000000-25e6cc490ffec05c4a72
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-1910000000-792e383cfc54a9b8ebd6
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ue9-1900000000-661b85ea2afa687f93a0
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udr-4900000000-098a637ebcf57aa77319
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4i-0000900000-be1710159c584212b699
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-052f-0000900000-bd4b9a1921d45f27be9d
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-0001900000-96106fbade202303433e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udl-0219400000-07d734cb9f459b083f55
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0f8i-1159000000-8e48b5ce1c715cfd049f
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-0006-0000900000-1d9e5a4995f9165bd72f

Taxonomy

Description
This compound belongs to the class of organic compounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Tetracyclines
Sub Class
Not Available
Direct Parent
Tetracyclines
Alternative Parents
Naphthacenes / Anthracenecarboxylic acids and derivatives / Tetralins / Aryl ketones / Dialkylarylamines / Cyclohexenones / 1-hydroxy-2-unsubstituted benzenoids / Aralkylamines / Vinylogous acids / Tertiary alcohols
show 8 more
Substituents
Tetracycline / Naphthacene / Tetracene / Anthracene carboxylic acid or derivatives / Tetralin / Tertiary aliphatic/aromatic amine / Aryl ketone / Dialkylarylamine / 1-hydroxy-2-unsubstituted benzenoid / Cyclohexenone
show 24 more
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
tetracyclines, tetracenomycin (CHEBI:50694) / Linear tetracyclines (C07225) / Linear tetracyclines (LMPK07000002)

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
The C-terminal tail plays a role in the affinity of the 30S P site for different tRNAs. Mutations that decrease this affinity are suppressed in the 70S ribosome.
Gene Name
rpsI
Uniprot ID
P0A7X3
Uniprot Name
30S ribosomal protein S9
Molecular Weight
14856.105 Da
References
  1. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ: The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88. [PubMed:14723559]
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Translation repressor activity, nucleic acid binding
Specific Function
One of two assembly initiator proteins for the 30S subunit, it binds directly to 16S rRNA where it nucleates assembly of the body of the 30S subunit.With S5 and S12 plays an important role in trans...
Gene Name
rpsD
Uniprot ID
P0A7V8
Uniprot Name
30S ribosomal protein S4
Molecular Weight
23468.915 Da
References
  1. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, Gin A, Karlowsky JA, Hoban DJ: The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004;64(1):63-88. [PubMed:14723559]
3. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Unknown
Actions
Inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Modulator
General Function
Protein domain specific binding
Specific Function
Potent proinflammatory cytokine. Initially discovered as the major endogenous pyrogen, induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation and cytokine production, ...
Gene Name
IL1B
Uniprot ID
P01584
Uniprot Name
Interleukin-1 beta
Molecular Weight
30747.7 Da
References
  1. Sadowski T, Steinmeyer J: Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes. J Rheumatol. 2001 Feb;28(2):336-40. [PubMed:11246672]
  2. Oringer RJ, Al-Shammari KF, Aldredge WA, Iacono VJ, Eber RM, Wang HL, Berwald B, Nejat R, Giannobile WV: Effect of locally delivered minocycline microspheres on markers of bone resorption. J Periodontol. 2002 Aug;73(8):835-42. [PubMed:12211491]
  3. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, Patel IR, Abramson SB: A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14014-9. [PubMed:8943052]
  4. Steinmeyer J, Daufeldt S, Taiwo YO: Pharmacological effect of tetracyclines on proteoglycanases from interleukin-1-treated articular cartilage. Biochem Pharmacol. 1998 Jan 1;55(1):93-100. [PubMed:9413935]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Iron ion binding
Specific Function
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name
ALOX5
Uniprot ID
P09917
Uniprot Name
Arachidonate 5-lipoxygenase
Molecular Weight
77982.595 Da
References
  1. Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z: Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport. 2004 Oct 5;15(14):2181-4. [PubMed:15371729]
  2. Song Y, Wei EQ, Zhang WP, Ge QF, Liu JR, Wang ML, Huang XJ, Hu X, Chen Z: Minocycline protects PC12 cells against NMDA-induced injury via inhibiting 5-lipoxygenase activation. Brain Res. 2006 Apr 26;1085(1):57-67. Epub 2006 Mar 30. [PubMed:16574083]
  3. Chu LS, Fang SH, Zhou Y, Yu GL, Wang ML, Zhang WP, Wei EQ: Minocycline inhibits 5-lipoxygenase activation and brain inflammation after focal cerebral ischemia in rats. Acta Pharmacol Sin. 2007 Jun;28(6):763-72. [PubMed:17506934]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
May play an essential role in local proteolysis of the extracellular matrix and in leukocyte migration. Could play a role in bone osteoclastic resorption. Cleaves KiSS1 at a Gly-|-Leu bond. Cleaves...
Gene Name
MMP9
Uniprot ID
P14780
Uniprot Name
Matrix metalloproteinase-9
Molecular Weight
78457.51 Da
References
  1. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW: Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain. 2002 Jun;125(Pt 6):1297-308. [PubMed:12023318]
  2. Sutton TA, Kelly KJ, Mang HE, Plotkin Z, Sandoval RM, Dagher PC: Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am J Physiol Renal Physiol. 2005 Jan;288(1):F91-7. Epub 2004 Sep 7. [PubMed:15353401]
  3. Koistinaho M, Malm TM, Kettunen MI, Goldsteins G, Starckx S, Kauppinen RA, Opdenakker G, Koistinaho J: Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J Cereb Blood Flow Metab. 2005 Apr;25(4):460-7. [PubMed:15674236]
  4. Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ, Lin E, Yang GY, Young WL: Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab. 2006 Sep;26(9):1157-64. Epub 2006 Jan 4. [PubMed:16395286]
  5. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC: Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006 Jul 17;7:56. [PubMed:16846501]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Vascular endothelial growth factor receptor binding
Specific Function
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of...
Gene Name
VEGFA
Uniprot ID
P15692
Uniprot Name
Vascular endothelial growth factor A
Molecular Weight
27042.205 Da
References
  1. Sasamura H, Takahashi A, Miyao N, Yanase M, Masumori N, Kitamura H, Itoh N, Tsukamoto T: Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma. Br J Cancer. 2002 Mar 4;86(5):768-73. [PubMed:11875741]
  2. Yao JS, Chen Y, Zhai W, Xu K, Young WL, Yang GY: Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: the role of ERK1/2, PI3K, and matrix metalloproteinases. Circ Res. 2004 Aug 20;95(4):364-71. Epub 2004 Jul 15. [PubMed:15256478]
  3. Rocchetti R, Talevi S, Margiotta C, Calza R, Corallini A, Possati L: Antiangiogenic drugs for chemotherapy of bladder tumours. Chemotherapy. 2005 Oct;51(6):291-9. Epub 2005 Oct 13. [PubMed:16224178]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Negative modulator
General Function
Endopeptidase activity
Specific Function
Thiol protease that cleaves IL-1 beta between an Asp and an Ala, releasing the mature cytokine which is involved in a variety of inflammatory processes. Important for defense against pathogens. Cle...
Gene Name
CASP1
Uniprot ID
P29466
Uniprot Name
Caspase-1
Molecular Weight
45158.215 Da
References
  1. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. [PubMed:10888929]
  2. Sanchez Mejia RO, Ona VO, Li M, Friedlander RM: Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 2001 Jun;48(6):1393-9; discussion 1399-401. [PubMed:11383749]
  3. Vincent JA, Mohr S: Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes. 2007 Jan;56(1):224-30. [PubMed:17192486]
  4. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. [PubMed:18977395]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Negative modulator
General Function
Phospholipase a2 activator activity
Specific Function
Involved in the activation cascade of caspases responsible for apoptosis execution. At the onset of apoptosis it proteolytically cleaves poly(ADP-ribose) polymerase (PARP) at a '216-Asp-|-Gly-217' ...
Gene Name
CASP3
Uniprot ID
P42574
Uniprot Name
Caspase-3
Molecular Weight
31607.58 Da
References
  1. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000 Jul;6(7):797-801. [PubMed:10888929]
  2. Arvin KL, Han BH, Du Y, Lin SZ, Paul SM, Holtzman DM: Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann Neurol. 2002 Jul;52(1):54-61. [PubMed:12112047]
  3. Dommergues MA, Plaisant F, Verney C, Gressens P: Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. Neuroscience. 2003;121(3):619-28. [PubMed:14568022]
  4. Lee SM, Yune TY, Kim SJ, Park DW, Lee YK, Kim YC, Oh YJ, Markelonis GJ, Oh TH: Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma. 2003 Oct;20(10):1017-27. [PubMed:14588118]
  5. Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Seigel GM, Kelly ME: An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Mol Pharmacol. 2004 Nov;66(5):1113-22. Epub 2004 Aug 10. [PubMed:15304547]
  6. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. [PubMed:18977395]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Negative modulator
General Function
Metal ion binding
Specific Function
Electron carrier protein. The oxidized form of the cytochrome c heme group can accept an electron from the heme group of the cytochrome c1 subunit of cytochrome reductase. Cytochrome c then transfe...
Gene Name
CYCS
Uniprot ID
P99999
Uniprot Name
Cytochrome c
Molecular Weight
11748.69 Da
References
  1. Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM: Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002 May 2;417(6884):74-8. [PubMed:11986668]
  2. Matsuki S, Iuchi Y, Ikeda Y, Sasagawa I, Tomita Y, Fujii J: Suppression of cytochrome c release and apoptosis in testes with heat stress by minocycline. Biochem Biophys Res Commun. 2003 Dec 19;312(3):843-9. [PubMed:14680842]
  3. Chu HC, Lin YL, Sytwu HK, Lin SH, Liao CL, Chao YC: Effects of minocycline on Fas-mediated fulminant hepatitis in mice. Br J Pharmacol. 2005 Jan;144(2):275-82. [PubMed:15665864]
  4. Heo K, Cho YJ, Cho KJ, Kim HW, Kim HJ, Shin HY, Lee BI, Kim GW: Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice. Neurosci Lett. 2006 May 8;398(3):195-200. Epub 2006 Feb 15. [PubMed:16469440]
  5. Mansson R, Hansson MJ, Morota S, Uchino H, Ekdahl CT, Elmer E: Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline. Neurobiol Dis. 2007 Jan;25(1):198-205. Epub 2006 Oct 24. [PubMed:17067803]
  6. Kim HS, Suh YH: Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. [PubMed:18977395]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenad...
Gene Name
SLC22A8
Uniprot ID
Q8TCC7
Uniprot Name
Solute carrier family 22 member 8
Molecular Weight
59855.585 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name
SLC22A11
Uniprot ID
Q9NSA0
Uniprot Name
Solute carrier family 22 member 11
Molecular Weight
59970.945 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulf...
Gene Name
SLC22A7
Uniprot ID
Q9Y694
Uniprot Name
Solute carrier family 22 member 7
Molecular Weight
60025.025 Da
References
  1. Babu E, Takeda M, Narikawa S, Kobayashi Y, Yamamoto T, Cha SH, Sekine T, Sakthisekaran D, Endou H: Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76. [PubMed:11855680]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18